Icecure Medical Ltd. ( (ICCM) ) has released its Q3 earnings. Here is a breakdown of the information Icecure Medical Ltd. presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
IceCure Medical Ltd. is a company specializing in the development and marketing of cryoablation technology, which uses liquid nitrogen to destroy tumors by freezing, offering a minimally invasive alternative to surgical tumor removal in areas such as breast, kidney, bone, and lung cancer.
IceCure Medical Ltd. has reported its financial and operational results for the nine months ending September 30, 2025, highlighting a significant milestone with the FDA’s marketing authorization for its ProSense® cryoablation system for treating low-risk breast cancer in women aged 70 and above. This development is expected to boost demand and expand the company’s market presence in the U.S. and globally.
Key financial metrics for the period show a revenue of $2.1 million, a decrease from the previous year due to reduced sales in Japan and other regions, although sales in Latin America increased. Gross profit declined to $626,000, with a gross margin of 30%. Operating expenses decreased to $11.5 million, resulting in a net loss of $10.8 million, similar to the previous year. The company successfully raised $10 million through a rights offering to support the commercialization of its ProSense® and XSense™ systems.
Strategic announcements include the expected rollout of ProSense® to 30 clinical and commercial sites across the U.S., pending FDA review, and potential additional reimbursement coverage. IceCure also received regulatory approval in Switzerland and plans a regulatory submission in Japan in 2026. The company continues to strengthen its intellectual property and expand its presence at major medical conferences.
Looking ahead, IceCure Medical is optimistic about the commercial traction of its ProSense® system following the FDA’s authorization. The company anticipates increased installations and procedure volumes, with ongoing efforts to expand its market reach and secure further regulatory approvals globally.